Section I. Human Immunodeficiency Virus Protease Inhibitors.- 1 The Road to Fortovase. A History of Saquinavir, the First Human Immunodeficiency Virus Protease Inhibitor.- 2 Clinical Experience with Human Immunodeficiency Virus Protease Inhibitors: Antiretroviral Results, Questions and Future Strategies.- 3 The Nature of Resistance to Human Immunodeficiency Virus Type-1 Protease Inhibitors.- 4 The Next Generation of Human Immunodeficiency Virus Protease Inhibitors: Targeting Viral Resistance.- Section II. Other Viral (Non ...
Read More
Section I. Human Immunodeficiency Virus Protease Inhibitors.- 1 The Road to Fortovase. A History of Saquinavir, the First Human Immunodeficiency Virus Protease Inhibitor.- 2 Clinical Experience with Human Immunodeficiency Virus Protease Inhibitors: Antiretroviral Results, Questions and Future Strategies.- 3 The Nature of Resistance to Human Immunodeficiency Virus Type-1 Protease Inhibitors.- 4 The Next Generation of Human Immunodeficiency Virus Protease Inhibitors: Targeting Viral Resistance.- Section II. Other Viral (Non-HIV) Protease Inhibitors.- 5 The Proteinases Encoded by Hepatitis C Virus as Therapeutic Targets.- 6 The Human Herpes-Virus Proteases.- 7 The 3C Proteinases of Picornaviruses and Other Positive-Sense, Single-Stranded RNA Viruses.- 8 Adenovirus Proteinase-Antiviral Target for Triple-Combination Therapy on a Single Enzyme: Potential Inhibitor-Binding Sites.- 9 Proteinases as Virulence Factors in Bacterial Diseases and as Potential Targets for Therapeutic Intervention with Proteinase Inhibitors.- 10 Parasite Proteases as Targets for Therapy.- Section III. (Non-Viral) Proteases Involved in Diseases.- 11 Host Proteinases as Targets for Therapeutic Intervention.- 12 The Role of Metalloprotease Inhibitors in Cancer and Chronic Inflammatory Diseases.- 13 The Tumor Necrosis Factor-? Converting Enzyme.- 14 Serine Elastases in Inflammatory and Vascular Diseases.- 15 Inhibitors of Thrombin and Factor Xa.- 16 Inhibitors of Papain-Like Cysteine Peptidases in Cancer.- 17 Caspases and Their Natural Inhibitors as Therapeutic Targets for Regulating Apoptosis.- 18 Proteasome and Apoptosis.- 19 Proteolytic Processing of the Amyloid Precursor Protein of Alzheimer's Disease.- 20 Presenilins and ?-Amyloid Precursor Protein-Proteolytically Processed Proteins Involved in the Generation of Alzheimer's Amyloid ? Peptide.
Read Less
Add this copy of Proteases as Targets for Therapy (Handbook of to cart. $13.97, Sold by Zubal Books rated 4.0 out of 5 stars, ships from Cleveland, OH, UNITED STATES, published 2000 by Springer.
Choose your shipping method in Checkout. Costs may vary based on destination.
Seller's Description:
401 pp., Hardcover, ex library, else text clean and binding tight. -If you are reading this, this item is actually (physically) in our stock and ready for shipment once ordered. We are not bookjackers. Buyer is responsible for any additional duties, taxes, or fees required by recipient's country.
Add this copy of Handbook of Experimental Pharmacology: Proteases as to cart. $38.14, good condition, Sold by Anybook rated 4.0 out of 5 stars, ships from Lincoln, UNITED KINGDOM, published 2000 by Springer.
Choose your shipping method in Checkout. Costs may vary based on destination.
Seller's Description:
This is an ex-library book and may have the usual library/used-book markings inside. This book has hardback covers. Clean from markings In good all round condition. No dust jacket. Please note the Image in this listing is a stock photo and may not match the covers of the actual item, 850grams, ISBN: 9783540661184.
Add this copy of Proteases as Targets for Therapy (Handbook of to cart. $59.40, good condition, Sold by Bonita rated 4.0 out of 5 stars, ships from Newport Coast, CA, UNITED STATES, published 2000 by Springer.
Add this copy of Proteases as Targets for Therapy (Handbook of to cart. $119.73, very good condition, Sold by LLU- BOOKSERVICE ANTIQUARIAN rated 5.0 out of 5 stars, ships from Wahlstedt, S-H, GERMANY, published 2000 by Springer.
Choose your shipping method in Checkout. Costs may vary based on destination.
Seller's Description:
Very good in very good dust jacket. This volume is the first to combine latest information on viral, microbial and cellular proteolytic enzymes as potential targets for human therapeutics. Proteases control a large array of physiological reactions, and are involved in a variety of pathological processes for which effective medications are currently needed and/or being sought after. Although protease inhibitors have been investigated for many years, few have been employed therapeutically. Recent break-through by HIV protease inhibitors as therapeutic drugs has re-encouraged the search for inhibitors of other proteolytic enzymes. Klaus von der Helm, who described the first viral protease has brought leading experts together to discuss not only the success and problems of clinical use and continuing prospects, but to review further potential drug targets. This volume provides detailed information and evaluations of key viral, bacterial, fungal, and cellular proteases as potential future drug candidates. TOC: I: HIV Protease Inhibitors (PI). -II: Other Viral (Non-HIV) Protease Inhibitors. -III: (Non-Viral) Proteases Involved in Diseases. Reihe/Serie Handbook of Experimental Pharmacology; Vol.140 Sprache englisch Maße 155 x 235 mm Einbandart gebunden Medizin Pharmazie Pharmakologie Arzneien Medikamente Arzneimittel Chemotherapie Chemotherapy drug design Pharmakologe Protease protease inhibitors Proteasen ISBN-10 3-540-66118-2 / 3540661182 ISBN-13 978-3-540-66118-4 / 9783540661184.